Luxdegalutamide

Description: Luxdegalutamide (ARV-766) is an orally available and effective protein degrader of protein hydrolysis-targeted chimeras (PROTAC).Luxdegalutamide degrades the wild-type androgen receptor AR, as well as AR LBD mutants including those associated with the most prevalent pathogenic AR L702H, H875Y and T878A mutations. Target: PROTACs, Androgen Receptor. Smiles: O([C@H]1C(C)(C)[C@H](NC(=O)C2=CC=C(C=C2)N3CCC(CN4CCN(CC4)C5=CC(F)=C(C(N[C@@H]6C(=O)NC(=O)CC6)=O)C=C5)CC3)C1(C)C)C7=CC(OC)=C(C#N)C=C7. References: Petrylak D P, et al. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). 2023.